Why has MSD's Keytruda sales growth slowed significantly in the European market over the past quarter?

Introduction

Keytruda's sales growth slowdown in the European market is a critical issue for MSD that requires thorough analysis. I'll approach this problem systematically, examining potential root causes and developing a comprehensive strategy to address the slowdown. My analysis will cover market dynamics, product positioning, competitive landscape, and internal factors that may be impacting Keytruda's performance.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might be a specific event or change that triggered this slowdown. Has there been any significant regulatory or reimbursement policy changes in key European markets recently?

Why it matters: Regulatory changes can dramatically impact drug sales, especially for high-cost treatments like Keytruda. Expected answer: Recent changes in reimbursement policies in Germany and France. Impact on approach: If confirmed, we'd need to focus on market access strategies and pricing negotiations.

• Considering Keytruda's broad indications, I'm curious about the sales breakdown. Has the slowdown been uniform across all approved indications, or are certain therapeutic areas more affected?

Why it matters: This helps identify if the issue is product-wide or specific to certain indications. Expected answer: Slowdown more pronounced in lung cancer and melanoma indications. Impact on approach: We'd need to investigate competitive pressures or clinical data updates in these specific areas.

• Given the competitive landscape in immuno-oncology, I'm wondering about market share trends. Has MSD's market share for Keytruda changed significantly compared to key competitors like Bristol Myers Squibb's Opdivo or Roche's Tecentriq?

Why it matters: This helps determine if the slowdown is MSD-specific or an industry-wide trend. Expected answer: Slight market share loss to newer entrants in some indications. Impact on approach: We'd need to focus on differentiation strategies and potentially new combination therapies.

• Considering the importance of clinical data in oncology, I'm thinking about recent trial results. Have there been any significant clinical trial outcomes (positive or negative) for Keytruda or its competitors in the past 6-12 months that might influence prescribing patterns?

Why it matters: New clinical data can quickly shift treatment preferences in oncology. Expected answer: Mixed results from some recent combination therapy trials. Impact on approach: We'd need to reassess our clinical development strategy and communication of trial results to healthcare providers.